GAIN THERAPEUTICS INC (GANX) Stock Price & Overview
NASDAQ:GANX • US36269B1052
Current stock price
The current stock price of GANX is 1.8 USD. Today GANX is down by -2.17%. In the past month the price decreased by -34.55%. In the past year, price increased by 6.95%.
GANX Key Statistics
- Market Cap
- 76.032M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.61
- Dividend Yield
- N/A
GANX Stock Performance
GANX Stock Chart
GANX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to GANX. When comparing the yearly performance of all stocks, GANX is a bad performer in the overall market: 77.78% of all stocks are doing better.
GANX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GANX. Both the profitability and financial health of GANX have multiple concerns.
GANX Earnings
GANX Forecast & Estimates
11 analysts have analysed GANX and the average price target is 7.75 USD. This implies a price increase of 330.67% is expected in the next year compared to the current price of 1.8.
GANX Groups
Sector & Classification
GANX Financial Highlights
Over the last trailing twelve months GANX reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 33.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -189.07% | ||
| ROE | -503.05% | ||
| Debt/Equity | 0.09 |
GANX Ownership
GANX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.02 | 367.796B | ||
| AMGN | AMGEN INC | 15.37 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.19 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.73 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.56 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.41 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GANX
Company Profile
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. The company is headquartered in Bethesda, Maryland and currently employs 23 full-time employees. The company went IPO on 2021-03-18. The firm is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Company Info
IPO: 2021-03-18
GAIN THERAPEUTICS INC
4800 Montgomery Lane, Suite 220
Bethesda MARYLAND 20814 US
CEO: Eric Richman
Employees: 21
Phone: 13015001556
GAIN THERAPEUTICS INC / GANX FAQ
Can you describe the business of GAIN THERAPEUTICS INC?
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. The company is headquartered in Bethesda, Maryland and currently employs 23 full-time employees. The company went IPO on 2021-03-18. The firm is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
What is the stock price of GAIN THERAPEUTICS INC today?
The current stock price of GANX is 1.8 USD. The price decreased by -2.17% in the last trading session.
Does GANX stock pay dividends?
GANX does not pay a dividend.
What is the ChartMill technical and fundamental rating of GANX stock?
GANX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does GAIN THERAPEUTICS INC belong to?
GAIN THERAPEUTICS INC (GANX) operates in the Health Care sector and the Biotechnology industry.
What is GAIN THERAPEUTICS INC worth?
GAIN THERAPEUTICS INC (GANX) has a market capitalization of 76.03M USD. This makes GANX a Micro Cap stock.
Can you provide the ownership details for GANX stock?
You can find the ownership structure of GAIN THERAPEUTICS INC (GANX) on the Ownership tab.